The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...

Rocket Pharmaceuticals, Inc.'s innovative therapies show promise after FDA setbacks. With potential $1B+ markets, RCKT offers ...

The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

Garner is a behavioral intervention scientist and an assistant professor of nutritional sciences.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Nasdaq’s determination is based on the Company meeting all other applicable requirements for listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The U.S. Food and Drug Administration (FDA) has granted approval for an expanded use of Ozempic® (semaglutide) injection, developed by pharmaceutical company Novo Nordisk (NYSE:NVO). The medication is ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...